Get the Stockscreener App
7.26
7.75%
-0.61
After Hours:
7.11
-0.15
-2.07%
Quoin Pharmaceuticals Ltd Adr stock is traded at $7.26, with a volume of 78,609.
It is down -7.75% in the last 24 hours and up +66.90% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$7.87
Open:
$7.64
24h Volume:
78,609
Relative Volume:
0.11
Market Cap:
$14.58M
Revenue:
-
Net Income/Loss:
$-17.10M
P/E Ratio:
-0.0307
EPS:
-236.7281
Net Cash Flow:
$-15.92M
1W Performance:
+18.63%
1M Performance:
+66.90%
6M Performance:
-14.59%
1Y Performance:
-4.78%
1-Day Range:
$7.10
$7.6869
1-Week Range:
$5.43
$8.00
52-Week Range:
$3.25
$41.80
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Compare QNRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNRX
Quoin Pharmaceuticals Ltd Adr
|
7.26 | 10.02M | 0 | -17.10M | -15.92M | -236.73 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases - Investing.com
Quoin Pharmaceuticals COO Denise Carter buys $99,991 in ADSs - Investing.com
Quoin Pharmaceuticals director Culverwell buys $29,992 in ADSs - Investing.com
Quoin Pharmaceuticals CFO Lawlor buys $49,990 in company stock - Investing.com
Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs - Investing.com India
Dow Gains 100 Points; Chicago PMI Falls In August - Sahm
Quoin Pharmaceuticals Stock Surges Friday: What's Happening? - Sahm
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals raises $30.8M in private placement - Investing.com
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million - Barchart.com
Quoin Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Barchart.com
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 - Barchart.com
Cash flow from investing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Book value per share of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Average basic shares outstanding of Quoin Pharmaceuticals. Ltd Sponsored ADR – LSX:A41BEM - TradingView
Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops - Sahm
Price to earnings forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome - Sahm
Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com - Investing.com India
QNRXQuoin Pharmaceuticals Ltd ADR Volatility & Greeks - Finviz
Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX) - TradingView
Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - Sahm
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market - Moomoo
Quoin Pharmaceuticals establishes Japan subsidiary for QRX003 - Investing.com
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program - Sahm
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals stock rises on rare disease IND filing By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals stock rises on rare disease IND filing - Investing.com
Number of shareholders of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals (QNRX) Earnings Date and Reports 2026 - marketbeat.com
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Sahm
Quoin Pharmaceuticals DRC News Today (QNRX) - Investing.com
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin - TipRanks
Unusual VolumeStock ScreenerNews - Finviz
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - Sahm
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program - TipRanks
Critical Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer |
Aug 31 '26 |
Buy |
4.88 |
20,490 |
99,991 |
37,713 |
| Lawlor Sally Bridget | Chief Financial Officer |
Aug 31 '26 |
Buy |
4.88 |
10,244 |
49,991 |
10,684 |
| Culverwell Anthony James | Director |
Aug 31 '26 |
Buy |
4.88 |
6,146 |
29,992 |
40,364 |
| LANGER DENNIS | Director |
Oct 14 '25 |
Buy |
8.49 |
15,152 |
128,640 |
15,153 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):